Krebs Biochemicals Reports Significant Revenue Decline and Increased Losses for Q2 & H1 FY26
Krebs Biochemicals reported a substantial drop in Q2 and H1 FY26 revenue to ₹4.17 crore and ₹5.48 crore, respectively, with increased losses to ₹(6.14) crore and ₹(11.47) crore. Vizag unit remains closed.
The substantial decline in revenue and increased losses indicate deteriorating financial health, which is a major concern for investors. The ongoing closure of a key manufacturing unit further exacerbates operational challenges and casts a shadow on recovery, leading to a high negative impact.
The company reported a significant decrease in revenue from operations and an increase in net losses for both the second quarter and the half-year ended September 30, 2025, compared to the previous year. Additionally, the continued closure of its Vizag manufacturing unit negatively impacts operational capacity and future prospects.
Krebs Biochemicals and Industries Limited announced the unaudited standalone financial results for the second quarter and half year ended September 30, 2025, approved by its Board of Directors on November 4, 2025. The statutory auditors issued an "Unmodified Report" on these results. Key financial highlights are: * For the quarter ended September 30, 2025, Revenue from Operations decreased to ₹416.74 lacs (₹4.17 crore) from ₹964.83 lacs (₹9.65 crore) in the same quarter last year. * The Loss before Tax for the quarter increased to ₹(614.28) lacs (₹(6.14) crore) compared to a loss of ₹(576.08) lacs (₹(5.76) crore) in the previous year's corresponding quarter. * For the half year ended September 30, 2025, Revenue from Operations was ₹548.09 lacs (₹5.48 crore), down from ₹1,285.52 lacs (₹12.86 crore) for the half year ended September 30, 2024. * The Loss before Tax for the half year increased to ₹(1,146.71) lacs (₹(11.47) crore) from a loss of ₹(1,093.20) lacs (₹(10.93) crore) in the same period last year. * Basic Earnings Per Share (EPS) for the quarter stood at ₹(2.85) and for the half year at ₹(5.32). * The company's Vizag manufacturing unit continues to be closed as per the Andhra Pradesh Pollution Control Board's order dated February 7, 2025.
What to do with a filing like this
Krebs Biochemicals and Industries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krebs Biochemicals and Industries Limited. Read the original for the full detail.